**Pancreatic Cancer: The Fortress Is Falling** Pancreatic cancer has long been oncology's most feared diagnosis — a tumor so dense and genetically stubborn that chemotherapy could barely bend its survival curves, leaving five-year survival rates mired in single digits. Its central driver, KRAS, spent decades labeled "undruggable." 2026 is rewriting that story. Revolution Medicines' Rasonque (daraxonrasib) earned FDA approval and a positive European recommendation after nearly doubling median survival to 13.2 months versus roughly 6.6 for chemotherapy — with gentler side effects. Tango Therapeutics then built on that foundation, reporting at ESMO 2026 that its vopimetostat paired with Rasonque produced an 82% tumor response rate, with 88% of patients alive and progression-free at nine months — all without chemotherapy. Meanwhile, musician Aloe Blacc is bootstrapping his own pancreatic cancer platform, a reminder that patient urgency still outpaces the pipeline. The implications ripple wide: validated targeted combinations are opening a lucrative commercial race, regulators and payers face fresh access questions, and investors are repricing the entire KRAS landscape. For biotech watchers, pancreatic cancer has transformed from a graveyard into oncology's most consequential battleground — and the momentum is audible.